Table 1.
Demographic, clinical features, and discontinuation of therapy.
| PsA Patients’ Characteristics and Treatment | 80 Patients |
|---|---|
| Demographic characteristics | |
| Age, years, mean ± SD, years | 50.1 ± 11.8 |
| Male sex, n. (%) | 24 (30.0) |
| BMI, mean ± SD, kg/m2 | 28.1 ± 5.4 |
| Obesity (BMI ≥ 30 kg/m2), n. (%) | 27 (33.8) |
| Smoking habit, n. (%) | 22 (27.5) |
| Clinical characteristics | |
| Disease duration median (IQR), years | 4 (9) |
| Disease duration ≤ 2 years, n. (%) | 30 (37.5) |
| Disease duration ≥ 5 years, n. (%) | 38 (47.5) |
| Disease duration ≥ 10 years, n. (%) | 21 (26.3) |
| HLA-B27, n. (%) | 5 (6.3) |
| Peripheral involvement, n. (%) | 80 (100.0) |
| Skin involvement, n. (%) | 68 (85.0) |
| Axial involvement, n. (%) | 25 (31.3) |
| Enthesis involvement, n. (%) | 35 (43.8) |
| Psoriatic onychopathy, n. (%) | 19 (23.8) |
| Comorbidities | |
| Comorbidity, n. (%) | 46 (57.5) |
| High blood pressure, n. (%) | 36 (45.0) |
| Type 2 diabetes, n. (%) | 17 (21.3) |
| Fatty liver disease, n. (%) | 17 (21.3) |
| Cardiovascular disease, n. (%) | 16 (20.0) |
| Dyslipidemia, n. (%) | 12 (15.0) |
| Kidney disease, n. (%) | 5 (6.3) |
| Previous treatment | |
| Previous therapy with NSAIDs n. (%) | 39 (48.8) |
| Previous therapy with GCs n. (%) | 45 (56.3) |
| Previous therapy with csDMARDs n. (%) | 65 (81.3) |
| Previous therapy with MTX n. (%) | 61 (76.3) |
| Previous therapy with bDMARDs n. (%) | 49 (61.3) |
| Previous therapy with tsDMARDs n. (%) | 6 (7.5) |
| Previous TNFi n. (%) | 46 (57.5) |
| Previous IL-12/23i n. (%) | 4 (5.0) |
| Previous IL-17i n. (%) | 12 (15.0) |
| Previous tsDMARDs n. (%) | 9 (11.3) |
| Failure to 1 bDMARD/tsDMARD n. (%) | 32 (40.0) |
| Failure to 2 bDMARDs/tsDMARDs n. (%) | 15 (18.8) |
| Failure to 3 or more bDMARDs/tsDMARDs n. (%) | 9 (11.3) |
| Ixekizumab treatment | |
| Ongoing at the last observation n. (%) | 43 (53.8) |
| Discontinuation due to inefficacy n. (%) | 25 (31.3) |
| Discontinuation due to primary inefficacy n. (%) | 9 (11.3) |
| Discontinuation due to secondary inefficacy n. (%) | 16 (20.0) |
| Discontinuation due to AEs n. (%) | 12 (15.0) |
Footnotes: PsA, psoriatic arthritis; BMI, body mass index; SD, standard deviation; IQR, interquartile range; HLA, Human Leukocyte Antigen; NSAID, non-steroidal anti-inflammatory drugs; GCs, Glucocorticoids; csDMARDs, conventional synthetic Disease-Modifying Antirheumatic Drugs; MTX, methotrexate; bDMARDs, biologic Disease-Modifying Antirheumatic Drugs; tsDMARDs, targeted synthetic Disease-Modifying Antirheumatic Drugs; TNFi, tumor necrosis factor inhibitor; IL-12/23i, interleukin 12/23 inhibitor; IL-17i, interleukin 17 inhibitor; AEs, adverse events.